BGM BGM Group Ltd. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BGM Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$3.72
52W High
$17.17
52W Low
$3.25
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$746.32M
P/E
N/A
ROE
-16.5%
Profit margin
-26.3%
Debt/Equity
0.0
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.
Key Strengths
Piotroski F-Score of 6/9 indicates stable financial health relative to distressed peers
Exceptionally strong liquidity with a Current Ratio of 7.05 and Quick Ratio of 5.94
Zero debt (Debt/Equity = 0.00), reducing solvency risk
Low Price/Book ratio of 2.01 compared to sector average ROE challenges
Insider sentiment at 40/100 suggests limited selling pressure
Key Risks
Severe profitability issues: -26.32% profit margin and -16.52% ROE
Catastrophic revenue decline of -56.90% YoY, far worse than peer average
Price/Sales of 24.99 is extremely high for a shrinking, unprofitable company
No Altman Z-Score available, creating uncertainty about bankruptcy risk
Lack of analyst coverage, target prices, and cash flow data limits transparency
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
27
Weak
25
20
30
58
0
AI Verdict
High-risk profile with deteriorating fundamentals and limited valuation support
Key drivers: Negative earnings and revenue trends, Absence of Altman Z-Score and cash flow metrics, Extremely high Price/Sales despite contraction, Strong liquidity and no debt provide partial offset
Confidence
88%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 2.01 is moderate in absolute terms
Watchpoints
- Price/Sales of 24.99 is unjustifiably high given negative growth and margins
- No Graham Number or Intrinsic Value available for benchmarking
- P/E and Forward P/E are N/A due to unprofitability
Future
20/100
Ref Growth rates
Positives
No standout positives identified.
Watchpoints
- Revenue Growth (YoY): -56.90%
- Q/Q Earnings Growth: -16.40%
- No analyst forecasts or target prices available
Past
30/100
Ref Historical trends
Positives
- 52-week low of $3.25 suggests potential downside containment
Watchpoints
- 5Y price change: -90.8%
- 1Y price change: -66.0%
- 6M price change: -64.4%
Health
58/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9 indicates operational stability
- Debt/Equity = 0.00 eliminates leverage risk
- Current Ratio of 7.05 and Quick Ratio of 5.94 show strong short-term liquidity
Watchpoints
- No Altman Z-Score available, limiting distress risk assessment
- ROE: -16.52%, ROA: -3.84%, indicating poor asset utilization
- Gross Margin: 2.92% — critically low for the sector
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- Payout Ratio: 0.00% — no return to shareholders
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.72
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BGM and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BGM
BGM Group Ltd.
Primary
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
BBNX
Beta Bionics, Inc.
Peer
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+12.7% | +40.6% | +28.3% | -4.5% | +2.4% | -6.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
2.01
P/S Ratio
24.99
EV/Revenue
2.32
EV/EBITDA
-29.15
Market Cap
$746.32M
Profitability
Profit margins and return metrics
Profit Margin
-26.32%
Operating Margin
-5.41%
Gross Margin
2.92%
ROE
-16.52%
ROA
-3.84%
Growth
Revenue and earnings growth rates
Revenue Growth
-56.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-16.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.0
Low debt
Current Ratio
7.05
Strong
Quick Ratio
5.94
Excellent
Cash/Share
$3.55
Quarterly Earnings History
EPS performance vs analyst estimates
2026-01-26
$N/A
Healthcare Sector Comparison
Comparing BGM against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-16.52%
This Stock
vs
-52.77%
Sector Avg
-68.7%
(Below Avg)
Profit Margin
-26.32%
This Stock
vs
-20.78%
Sector Avg
+26.7%
(Superior)
Debt to Equity
0.0
This Stock
vs
6.16
Sector Avg
-100.0%
(Less Debt)
Revenue Growth
-56.9%
This Stock
vs
137.39%
Sector Avg
-141.4%
(Slower)
Current Ratio
7.05
This Stock
vs
3.36
Sector Avg
+109.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | |
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 | |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $819.3M | - | -45.9% | -289.4% | $4.26 |
Past News Coverage
Recent headlines mentioning BGM from our newsroom.
Newest → oldest
No matching news yet.